RenovoRx Q3 net loss narrows to $1.4M on warrant gain; TIGeR-PaC trial advances

RenovoRx, Inc.

2023-Q3 EPS reported -$0.69

Net loss of $1.4M vs $2.1M YoY; includes $1.5M gain on fair value of common warrants.
Cash and equivalents $3.2M as of Sept 30, 2023; shares outstanding 10.7M.
R&D expense $1.6M, up 100% YoY, driven by Phase III TIGeR-PaC trial costs.
Phase III TIGeR-PaC trial for pancreatic cancer continues after interim analysis recommended continuation.
Collaboration with Imugene to expand TAMP platform into immunotherapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.